Abstract
Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Current Neuropharmacology
Title: Startle Response Modulation as a Behavioral Tool in Neuropharmacology
Volume: 1 Issue: 2
Author(s): M. Koch and M. Fendt
Affiliation:
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Abstract: Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Export Options
About this article
Cite this article as:
Koch M. and Fendt M., Startle Response Modulation as a Behavioral Tool in Neuropharmacology, Current Neuropharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570159033477161
DOI https://dx.doi.org/10.2174/1570159033477161 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research PET Evaluation of Late Cerebral Effect in Advanced Radiation Therapy Techniques for Cranial Base Tumors
Current Radiopharmaceuticals Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media
Current Immunology Reviews (Discontinued) Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective
Current Pharmaceutical Design Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Current HIV Research Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia
CNS & Neurological Disorders - Drug Targets Cannabinoids and Psychosis
Current Pharmaceutical Design One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study
Current Alzheimer Research A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of Marijuana Use on Memory in HIV-Infected Patients: A Comprehensive Review of the HIV and Marijuana Literatures
Current Drug Abuse Reviews Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology Microfluidic Devices for Automation of Assays on Drosophila Melanogaster for Applications in Drug Discovery and Biological Studies
Current Pharmaceutical Biotechnology Neurobiology of Sleep Fragmentation: Cortical and Autonomic Markers of Sleep Disorders
Current Pharmaceutical Design SUBJECT INDEX
Current Neuropharmacology